tiprankstipranks

Immunocore price target lowered to $33 from $38 at Mizuho

Mizuho lowered the firm’s price target on Immunocore (IMCR) to $33 from $38 and keeps a Neutral rating on the shares. The firm’s thesis on Immunocore remains unchanged, and while Mizuho views Immunocre as a pioneer and leader in the development of T-cell receptor-based therapeutics for cancer, overall lack of meaningful clinical newsflow over the next 12-15 months for the company makes it difficult to see why its shares should outperform.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue